Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: Effects on mouse mammary tumor cell line MM2 in vitro and in vivo

Anti-Cancer Drugs

Volumn 12, Issue 8, 2001, Pages 691-698

  Takeda, Yasutaka ^a   Yoshizaki, Iwao ^a   Nonaka, Yasumasa ^a   Yanagie, Hironobu ^a   Matsuzawa, Akio ^a   Eriguchi, Masazumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 Fluorouracil; 5 Fluorouracil derivatives; Docetaxel; Mouse mammary tumor; Oral administration

Indexed keywords

ANTINEOPLASTIC AGENT; CARMOFUR; DOCETAXEL; DOXIFLURIDINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; PHOSPHORYLASE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG SYNERGISM; FEMALE; FLOXURIDINE; FLUOROURACIL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; PACLITAXEL; PRODRUGS; TAXOIDS; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034856122     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200109000-00008     Document Type: Article

References (31)

1. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC
2. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
3. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
4. Docetaxel (Taxotere). A review of preclinical and clinical experience. Part I: Preclinical experience
5. A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies
6. Docetaxel (Taxotere): An overview of first-line monotherapy
7. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC
8. Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination
9. Docetaxel in combination chemotherapy for metastatic breast cancer
10. Docetaxel/doxorubicin/cydophosphamide in the treatment of metastatic breast cancer
11. The synthesis of 5-fluoropyrimidines
12. Evolution in the treatment of advanced breast cancer
13. Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracyclines-based chemotherapy: A phase I, dose-finding study
14. A case of metastatic breast cancer achieving complete response by combination therapy with 5′-deoxy-5-fluorouridine and cyclophosphamide
15. Infusional 5-fluorouracil in breast cancer
16. Methods for studying cell death and viability in primary neuronal cultures
17. Testing for synergism over a range of fixed ratio drug combinations: Replacing the isobologram
18. Protein measurement with the Folin phenol reagent
19. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine
20. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
21. 5-Substituted-2,2′-anhydrouridines potent inhibitors uridine phosphorylase
22. Effects of Taxotere on murine and human tumor cell lines
23. Preclinical evaluation of docetaxel (Taxotere)
24. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors
25. A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck
26. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer
27. Developments in the treatment of gastric cancer in Europe
28. Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts
29. Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue
30. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
31. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models